city New Delhi India hospital covid-19 recommendations patient city New Delhi India

₹103 per tablet. 10 things to know

Reading now: 665
www.livemint.com

NEW DELHI : Having received the manufacturing and marketing approval from the Drugs Controller General of India (DCGI), drug firm Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 patients.

Price at ₹103 per tablet, the prescription-based drug will be available as a 200 mg tablet at an MRP of ₹3,500 for a strip of 34 tablets.10 things to know about the new Covid-19 drug:1) The recommended dose of Favipiravir is 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA